IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+12.89%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$317M
AUM Growth
+$317M
(-3.5%)
Cap. Flow
-$31.6M
Cap. Flow
% of AUM
-9.97%
Top 10 Holdings %
Top 10 Hldgs %
36.88%
Holding
89
New
29
Increased
20
Reduced
19
Closed
19
Top Buys
| 1 |
Revvity
RVTY
|
$10M |
| 2 |
Abbott
ABT
|
$6.53M |
| 3 |
Sanofi
SNY
|
$6.27M |
| 4 |
Centene
CNC
|
$5.54M |
| 5 |
eHealth
EHTH
|
$5.53M |
Top Sells
| 1 |
Quest Diagnostics
DGX
|
$13.7M |
| 2 |
LHCG
LHC Group LLC
LHCG
|
$10.6M |
| 3 |
Bristol-Myers Squibb
BMY
|
$9.05M |
| 4 |
Danaher
DHR
|
$7.96M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$7.65M |
Sector Composition
| 1 | Healthcare | 88.17% |
| 2 | Energy | 5.03% |
| 3 | Financials | 1.75% |
| 4 | Consumer Discretionary | 0.61% |
| 5 | Technology | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LHCG
1
DELISTED
LHC Group LLC
LHCG
| $15.9M | 4.88% | 75,000 -50,000 | -40% | -$10.6M |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $14.1M | 4.3% | 230,000 +35,000 | +18% | +$2.14M |
|
|
3
Revvity
RVTY
$10.5B
| $13.8M | 4.22% | 110,000 +80,000 | +267% | +$10M |
|
|
4
Abbott
ABT
$231B
| $12M | 3.66% | 110,000 +60,000 | +120% | +$6.53M |
|
|
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.2M | 3.43% | 150,000 -25,000 | -14% | -$1.87M |
|
6
Humana
HUM
$36.5B
| $10.8M | 3.29% | 26,000 +6,000 | +30% | +$2.48M |
|
|
CCXI
7
DELISTED
ChemoCentryx, Inc.
CCXI
| $10.1M | 3.1% | 185,000 +35,000 | +23% | +$1.92M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $9.73M | 2.98% | 105,000 -5,000 | -5% | -$464K |
|
9
Cencora
COR
$56.5B
| $9.69M | 2.96% | 100,000 +10,000 | +11% | +$969K |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $9.47M | 2.9% | 68,000 -7,000 | -9% | -$975K |
|
11
McKesson
MCK
$85.4B
| $9.23M | 2.82% | 62,000 +37,000 | +148% | +$5.51M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.13M | 2.79% | 120,000 +40,000 | +50% | +$3.04M |
|
13
Merck
MRK
$210B
| $8.3M | 2.54% | 100,000 +25,000 | +33% | +$2.07M |
|
14
Charles River Laboratories
CRL
$8.04B
| $7.47M | 2.29% | 33,000 -22,000 | -40% | -$4.98M |
|
15
Zimmer Biomet
ZBH
$21B
| $6.81M | 2.08% | 50,000 +15,000 | +43% | +$2.04M |
|
|
GWPH
16
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $6.33M | 1.94% | 65,000 -10,000 | -13% | -$974K |
|
|
17
Sanofi
SNY
$121B
| $6.27M | 1.92% | +125,000 | New | +$6.27M |
|
18
Envista
NVST
$3.52B
| $6.17M | 1.89% | 250,000 +75,000 | +43% | +$1.85M |
|
19
Denali Therapeutics
DNLI
$2.23B
| $5.91M | 1.81% | 165,000 +35,000 | +27% | +$1.25M |
|
|
20
Centene
CNC
$14.3B
| $5.54M | 1.69% | +95,000 | New | +$5.54M |
|
|
21
eHealth
EHTH
$118M
| $5.53M | 1.69% | +70,000 | New | +$5.53M |
|
22
Insulet
PODD
$23.9B
| $5.21M | 1.59% | 22,000 +4,000 | +22% | +$946K |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.98M | 1.52% | 30,000 -20,000 | -40% | -$3.32M |
|
24
Natera
NTRA
$23.1B
| $4.77M | 1.46% | +66,000 | New | +$4.77M |
|
25
Cytokinetics
CYTK
$4.23B
| $4.33M | 1.32% | 200,000 -140,000 | -41% | -$3.03M |
|